You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 130 No. 12, December 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (31)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Head & Neck Cancer
 •Neoplasms of Head & Neck
 •Radiology of Head & Neck
 •Prognosis/ Outcomes
 •PET/ SPECT Imaging
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

FDG-PET Prediction of Head and Neck Squamous Cell Cancer Outcomes

David L. Schwartz, MD; Joseph Rajendran, MD; Bevan Yueh, MD, MPH; Marc D. Coltrera, MD; Michael LeBlanc, PhD; Janet Eary, MD; Kenneth Krohn, PhD

Arch Otolaryngol Head Neck Surg. 2004;130:1361-1367.

Objective  To confirm that high pretreatment uptake of 2-deoxy-2[18F]fluoro-D-glucose (FDG) detected by positron emission tomography (PET) measured at the primary head and neck squamous cell carcinoma (HNSCC) and at metastatic nodal disease predicts poor outcomes for HNSCC.

Design and Patients  We enrolled 63 consecutive patients with a histological diagnosis of HNSCC (including tumors of the oral cavity, oropharynx, larynx, and hypopharynx) from September 2000 through June 2003, into a prospective institutional imaging trial. Fifty-four patients (86%) underwent a baseline FDG-PET scan before curative treatment and were eligible for analysis.

Results  A primary tumor standardized uptake value (SUV) of greater than 9.0 predicted inferior local recurrence-free survival (P = .02) and disease-free survival (P = .03). Nodal SUV dichotomized according to the cohort median of 6.1 did not predict for either disease outcome (P = .71 and P = .98, respectively). On proportional hazards analysis, local recurrence and disease event hazard ratios for a primary tumor SUV of 9.0 or greater remained significant or at borderline significance when adjusted for nodal SUV or other clinical covariates.

Conclusions  Our findings support an association between baseline primary tumor FDG SUV and HNSCC outcomes. In contrast, nodal FDG SUV was not predictive. Primary tumor FDG SUV is a promising prognostic factor and may establish the need for intensified locoregional therapy in individual patients. Multi-institutional imaging trials and further characterization of the biology responsible for elevated FDG uptake in HNSCC will be necessary to confirm the prognostic utility of FDG-labeled PET.


Author Affiliations: Radiation Oncology Service (Dr Schwartz), Surgical and Perioperative Care Service (Drs Yueh and Coltrera), and Health Services Research & Development Service (Dr Yueh), Veterans Affairs Puget Sound Health Care System, and Department of Radiation Oncology (Dr Schwartz), Division of Nuclear Medicine, Department of Radiology (Drs Rajendran and Eary), and Departments of Otolaryngology–Head and Neck Surgery (Drs Yueh and Coltrera), Biostatistics (Dr LeBlanc), and Radiology (Dr Krohn), University of Washington, Seattle.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of Whole-Body PET/CT, Dedicated High-Resolution Head and Neck PET/CT, and Contrast-Enhanced CT in Preoperative Staging of Clinically M0 Squamous Cell Carcinoma of the Head and Neck
Rodrigues et al.
JNM 2009;50:1205-1213.
ABSTRACT | FULL TEXT  

Dose Painting in Radiotherapy for Head and Neck Squamous Cell Carcinoma: Value of Repeated Functional Imaging with 18F-FDG PET, 18F-Fluoromisonidazole PET, Diffusion-Weighted MRI, and Dynamic Contrast-Enhanced MRI
Dirix et al.
JNM 2009;50:1020-1027.
ABSTRACT | FULL TEXT  

Prognostic Value of 18F-FDG PET in Patients with Head and Neck Squamous Cell Cancer
Torizuka et al.
Am. J. Roentgenol. 2009;192:W156-W160.
ABSTRACT | FULL TEXT  

The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion
Silva et al.
Cancer Res. 2009;69:2677-2684.
ABSTRACT | FULL TEXT  

Intratumoral Metabolic Heterogeneity of Cervical Cancer
Kidd and Grigsby
Clin. Cancer Res. 2008;14:5236-5241.
ABSTRACT | FULL TEXT  

Whole-Tumor Perfusion CT Parameters and Glucose Metabolism Measurements in Head and Neck Squamous Cell Carcinomas: A Pilot Study Using Combined Positron-Emission Tomography/CT Imaging
Bisdas et al.
Am. J. Neuroradiol. 2008;29:1376-1381.
ABSTRACT | FULL TEXT  

PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
Toner and Hicks
The Oncologist 2008;13:22-26.
ABSTRACT | FULL TEXT  

FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma
de Geus-Oei et al.
Ann Oncol 2006;17:1650-1655.
ABSTRACT | FULL TEXT  

Acid-mediated tumor invasion: a multidisciplinary study.
Gatenby et al.
Cancer Res. 2006;66:5216-5223.
ABSTRACT | FULL TEXT  

Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography
Leboulleux et al.
J. Clin. Endocrinol. Metab. 2006;91:920-925.
ABSTRACT | FULL TEXT  

Controversies: Is There a Role for Positron-Emission Tomographic CT in the Initial Staging of Head and Neck Squamous Cell Carcinoma?
Mukherji and Bradford
Am. J. Neuroradiol. 2006;27:243-245.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.